Peptide LocalCompare price, evidence & access
Search /Compare vendors
Regions/Global status checker
One name + one destination

Peptide status
by country.

Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.

Identity+Destination=Verification route
41tracked names
42country guides
3separate evidence lanes
99official source routes
Global source router

Two selections. No category shortcuts.

Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.

Status check updated to PT-141 / Bremelanotide in Italia. Research listing separated from medicine authorization requirements in Italy.

Current source route

PT-141 / Bremelanotide in Italia

Open exact country guide
Direct answer / Italia

Can you buy PT-141 / Bremelanotide in Italia?

Research listing separated from medicine authorization requirements in Italy

The 10 mg PT-141 research listings tracked here are not the US VYLEESI prescription product and do not inherit its FDA approval. AIFA states that a medicinal product must have marketing authorization from AIFA or the European Commission before it can be marketed in Italy. The linked Italian records must be searched for the exact product and presentation. They do not establish that a same-name online vial is authorized, available, lawful, or equivalent to VYLEESI.

  1. 01
    Resolve the nameResearch price board
  2. 02
    Check ItaliaPT-141 research identity and Italian medicine authorization boundary
  3. 03
    Verify the exact offerProduct, seller, and supply route must match
Identity recordUS research-market identity with a separate FDA-approved medicine record

What PT-141 / Bremelanotide resolves to

This record resolves seller-labelled 10 mg PT-141 research listings. VYLEESI is a separate FDA-approved bremelanotide prescription product with a 1.75 mg presentation, defined indication, label, and regulated supply chain. The research listings do not inherit that approval.

Evidence lane
Research price board
Current record
2 of 3 rows in stock
Checked
Jul 23, 2026
PT 141BremelanotideVyleesi
Destination recordI registri AIFA e ministeriali devono coincidere

What Italia still has to prove

Guida italiana all'uso della banca dati AIFA e dell'elenco ministeriale delle farmacie online prima di confrontare un prodotto o un venditore collegato ai peptidi.

Comparison mode
EUR / registri AIFA e Ministero della Salute
Price coverage
Nessuna tabella qualificata di venditori in Italia
Guide updated
18 luglio 2026
Product recordBanca dati AIFA MedicinaliAgenzia Italiana del Farmaco ↗Seller or supply recordVenditori online di medicinali autorizzatiMinistero della Salute ↗
Country-specific evidence found2 records attached to this exact check
Result boundaryIdentity match ≠ destination approval ≠ verified seller

This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.

Popular starting points

Open a common peptide and country check.

Each selection has a shareable URL, so you can send someone the exact peptide and destination without losing the identity or country context.

01CagriSema in South AfricaInvestigational clinical program02CagriSema in PortugalInvestigational clinical program03Retatrutide in ArgentinaInvestigational clinical program04Melanotan II in ItaliaUS research-market identity05PT-141 / Bremelanotide in ItaliaUS research-market identity with a separate FDA-approved medicine record06CJC-1295 DAC in FranceUS research-market identity07BPC-157 in FranceUS research-market identity08BPC-157 in DeutschlandUS research-market identity09Retatrutide in MéxicoInvestigational clinical program10Mazdutide in 中国China-approved medicine and active clinical program11Ecnoglutide in 中国China-approved medicine and active development program12Enicepatide in FranceInvestigational clinical program13Eloralintide in DeutschlandInvestigational clinical program14Tirzepatide in CanadaUS FDA medicine reference15Cagrilintide in United KingdomInvestigational clinical program16Petrelintide in DeutschlandInvestigational clinical program17MariTide in AustraliaInvestigational clinical program18Survodutide in FranceInvestigational clinical program19VK2735 in United StatesInvestigational clinical program20Pemvidutide in United StatesInvestigational clinical program21Semaglutide in الإمارات العربية المتحدةProduct-specific approved medicine records in multiple jurisdictions22Semaglutide in FranceProduct-specific approved medicine records in multiple jurisdictions23Semaglutide in CanadaProduct-specific approved medicine records in multiple jurisdictions24TB-500 in United StatesUS research-market identity25TB-500 in CanadaUS research-market identity26GHK-Cu in CanadaUS research-market identity27Semax in South AfricaUS research-market identity28Melanotan II in AustraliaUS research-market identity29MOTS-c in CanadaUS research-market identity30Tesamorelin in United StatesUS research-market identity with a separate FDA-licensed medicine record31AOD-9604 in South AfricaUS research-market identity with a failed oral obesity program and no FDA-approved drug32Ipamorelin in CanadaUS research-market identity33Selank in South AfricaUS research-market identity34PT-141 / Bremelanotide in United StatesUS research-market identity with a separate FDA-approved medicine record35CJC-1295 no DAC in CanadaUS research-market identity36CJC-1295 DAC in South AfricaUS research-market identity
Direct answers

What a country check means.

The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.

01

Is BPC-157 legal in every European country?

No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.

02

Is retatrutide available as an approved medicine?

The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.

03

Does a tirzepatide record prove local availability?

No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.

Why the split matters

A matching name is only the first record.

  1. 01

    Resolve identity

    Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.

  2. 02

    Resolve destination

    Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.

  3. 03

    Resolve the exact offer

    Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.

Continue the evidence trail
Search the complete peptide database ↗Compare all five world regions ↗Open all country, province, state, region, and city guides ↗